Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay

Hepatology

Volumn 48, Issue 5, 2008, Pages 1549-1557

  Mayo, Marlyn J ^a,p   Parkes, Julie ^b   Adams Huet, Beverley ^a   Combes, Burton ^a,b   Mills, A S ^a   Markin, Rodney S ^c   Rubin, Raphael ^d   Wheeler, Donald ^e   Contos, Melissa ^a   West, A B ^f   Saldana, Sandra ^b,g   Getachew, Yonas ^h   Butsch, Robert ^a   Luketic, Velimir ^a   Peters, Marion ⁱ   Di Bisceglie, Adrian ^j   Bass, Nathan ^j   Lake, John ^k   Boyer, Thomas ^l   Martinez, Enrique ^m   Boyer, James ⁿ   Garcia Tsao, Guadalupe ^g   Barnes, David ^g   Rosenberg, William M ^o   more..

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h LOMA LINDA UNIVERSITY   (United States)

ⁱ VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^m UNIVERSITY OF ARIZONA   (United States)

ⁿ Atlanta Gastroenterology Associates   (United States)

^o LERNER RESEARCH INSTITUTE   (United States)

^p UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; HYALURONIC ACID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ADULT; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAYO RISK SCORE; MODEL FOR END STAGE LIVER DISEASE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SCORING SYSTEM; VARICOSIS; ALGORITHM; BILIARY CIRRHOSIS; BIOPSY; BLOOD; FIBROSIS; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ALGORITHMS; BILIRUBIN; BIOPSY; DISEASE PROGRESSION; FIBROSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, BILIARY; METHOTREXATE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROGNOSIS; TREATMENT OUTCOME;

EID: 56149116412     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22517     Document Type: Article

References (27)

1. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128:297-303.
2. McHutchison J, Poynard T, Afdhal N, International Fibrosis Group Meeting Participants. Fibrosis as an end point for clinical trials in liver disease: A report of the international fibrosis group. Clin Gastroenterol Hepatol 2006;4:1214-1220.
3. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004;127:1704-1713.
4. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. Diagnostic value of biochemical markers (Fibro Test-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:6.
5. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005;3:167-174.
6. Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U, et al. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003;39:179-186.
7. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006;52: 1887-1896.
8. Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, et al. Methotrexate (MTZ) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. HEPATOLOGY 2005;42:1184-1193.
9. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22: 696-699.
10. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A non-parametric approach. Biometrics 1988;44:837-845.
11. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:103.
12. Popper H, Schaffner F. Nonsuppurative destructive chronic cholangitis and chronic hepatitis. In: Popper H, Schaffner F, eds. Progress in Liver Diseases, vol 3. New York: Grune & Stratton, Inc.; 1970:336-354.
13. Scheuer PJ. Primary biliary cirrhosis. Proc R Soc Med 1967;60:1257.
14. Zein CO, Angulo P, Lindor KD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol 2003;1: 89-95.
15. Imbert-Bismut F, Ratzui V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, for the MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001; 357:1069-1075.
16. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006;55:1650-1660.
17. Zaman A, Rosen HR, Ingram K, Corless CL, Oh E, Smith K. Assessment of FIBROSpectII to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 2007;120:2809-2814.
18. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers HEPATOLOGY 2008;47:455-460.
19. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. HEPATOLOGY 2007;45:846-854.
20. Poynard R, Imbert-Bismut I, Ratzui V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis inpatients infected by hepatitis C virius: Longitudinal validation in a randomized trial. J Virol Hepatitis 2002;9:128-133.
21. Poynard T, McHutchison J, Manns M, Myers RP, Albreacht J. Biochemcial surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. HEPATOLOGY 2003;38:481-492.
22. Myers RP, Ratzui V, Imbert-Bismut F, Charlotte F, Poynard T, for the MULTIVIRC group. Biochemical markers of liver fibrosis: A comparison with historical features in patients with chronic hepatitis c. Am J Gastroenterol 2002;97:2419-2425.
23. Myers RP, de Torres M, Imbert-Bismut F, Ratzui V, Charlotte F, Poynard T, et al. Biochemical markers of fibrosis in patient with chronic hepatitis C: A comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci 2003;48:146-153.
24. Scheuer PJ. Liver biopsy size matters in chronic hepatitis: Bigger is better. HEPATOLOGY 2003;38:1356-1357.
25. Maharaj B, Maharaj RJ, Leary WP, Coppan RM, Naran AD, Pirie D, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986;8480:523-525.
26. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003;38:1449-1457.
27. Garrido MC, Hubscher SG. Accuracy of staging in primary biliary cirrhosis. J Clin Pathol 1996;49:556-559.